MedKoo Biosciences

About us  |  Services  |  Products  |  News  |  Careers  |  Contact us

 

 

 


 

Back to products

 

 

Browse products

Approved anticancer agents

Anticancer agents in trials

Anticancer molecular libraries

 


Other drug agents

Drug intermediates

Bio-reagents and biochemicals

 


 

 

 

 

 

 

MedKoo product information:

 

 Vinorelbine tartrate

  

Vinorelbine tartrate is the ditartrate salt of a semisynthetic vinca alkaloid derived from the leaves of the periwinkle plant (Vinca rosea) with antineoplastic activity. Vinorelbine binds to tubulin, thereby inhibiting tubulin polymerization into microtubules and spindle formation and resulting in apoptosis of susceptible cancer cells. Inhibition of mitotic microtubules correlates with antitumor activity, whereas inhibition of axonal microtubules seems to correlate with vinorelbine's neurotoxicity. Compared to related vinca alkaloids, vinorelbine is more selective against mitotic than axonal microtubules in vitro, which may account for its decreased neurotoxicity. This agent is also a radiation-sensitizing agent. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

   

MedKoo Cat#:  100930

Name:  Vinorelbine tartrate

CAS#:  71486-22-1 (Vinorelbine); 125317-39-7 (Vinorelbine tartrate)

 

Synonym:  navelbine ditartrate; vinorelbine tartrate.   US brand name: Navelbine.  Foreign brand names: Biovelbin;  Eunades.   Abbreviations: NVB;   VNB.  Code name: KW-2307.

   

IUPAC/Chemical name:

(3aR,3a1R,4R,5S,5aR,10bR)-methyl 4-acetoxy-3a-ethyl-9-((2R,8S)-4-ethyl-8-(methoxycarbonyl)-1,3,6,7,8,9-hexahydro-2,6-methanoazecino[4,3-b]indol-8-yl)-5-hydroxy-8-methoxy-6-methyl-3a,3a1,4,5,5a,6,11,12-octahydro-1H-indolizino[8,1-cd]carbazole-5-carboxylate bis((2R,3R)-2,3-dihydroxysuccinate)

   

Chemical structure:

Theoretical analysis :

 

 

Vinorelbine

Chemical Formula: C45H54N4O8

Exact Mass: 778.39416

Molecular Weight: 778.93

Elemental Analysis: C, 69.39; H, 6.99; N, 7.19; O, 16.43

  

Vinorelbine tartrate

Chemical Formula: C53H66N4O20

Molecular Weight: 1079.10

Elemental Analysis: C, 58.99; H, 6.16; N, 5.19; O, 29.65

  

  

Availability and price:

 

Vinorelbine tartrate is available

 

For quotation, question, and order, please send email to sales@medkoo.com to describe your needs. A representative will respond your email shortly. We offer significant discount for larger quantity order.

 

Quality control data:

Product will be shipped with supporting analytical data.

 

 

Information about this agent

 

DRUG DESCRIPTION

NAVELBINE (vinorelbine tartrate) Injection is for intravenous administration. Each vial contains vinorelbine tartrate equivalent to 10 mg (1-mL vial) or 50 mg (5-mL vial) vinorelbine in Water for Injection. No preservatives or other additives are present. The aqueous solution is sterile and nonpyrogenic. Vinorelbine tartrate is a semi-synthetic vinca alkaloid with antitumor activity. The chemical name is 3',4'-didehydro-4'-deoxy-C'-norvincaleukoblastine [R-(R*,R*)-2, 3-dihydroxybutanedioate (1:2)(salt)]. vinorelbine tartrate is a white to yellow or light brown amorphous powder with the molecular formula C45H54N4O82C4H6O6 and molecular weight of 1079.12. The aqueous solubility is > 1,000 mg/mL in distilled water. The pH of NAVELBINE Injection is approximately 3.5.

 

Oral formulation

An oral formulation has been marketed and registered in most European coutries for the same settings. It has similar efficacy as the intravenous formulation, avoids venous toxicities of an infusion and is easier to take. from: http://en.wikipedia.org/wiki/Vinorelbine.

 

CLINICAL PHARMACOLOGY

Vinorelbine is a vinca alkaloid that interferes with microtubule assembly. The vinca alkaloids are structurally similar compounds comprised of 2 multiringed units, vindoline and catharanthine. Unlike other vinca alkaloids, the catharanthine unit is the site of structural modification for vinorelbine. The antitumor activity of vinorelbine is thought to be due primarily to inhibition of mitosis at metaphase through its interaction with tubulin. Like other vinca alkaloids, vinorelbine may also interfere with: 1) amino acid, cyclic AMP, and glutathione metabolism, 2) calmodulin-dependent Ca++-transport ATPase activity, 3) cellular respiration, and 4) nucleic acid and lipid biosynthesis. In intact tectal plates from mouse embryos, vinorelbine, vincristine and vinblastine inhibited mitotic microtubule formation at the same concentration (2 M), inducing a blockade of cells at metaphase. Vincristine produced depolymerization of axonal microtubules at 5 M, but vinblastine and vinorelbine did not have this effect until concentrations of 30 M and 40 M, respectively. These data suggest relative selectivity of vinorelbine for mitotic microtubules.

 

History

Vinorelbine was invented by the pharmacist Pierre Potier and his team from the CNRS in France in the 1980s and was licensed to the oncology department of the Pierre Fabre Group. The drug was approved in France in 1989 under the brand name Navelbine for the treatment of non-small cell lung cancer. It gained approval to treat metastatic breast cancer in 1991. Vinorelbine received approval by the United States Food and Drug Administration (FDA) in December 1994 sponsored by Burroughs Wellcome Company. Pierre Fabre Group now markets Navelbine in the U.S. where the drug went generic in February 2003. In most European countries, it is approved to treat non-small cell lung cancer and breast cancer. from: http://en.wikipedia.org/wiki/Vinorelbine.

 

References


 

 

 

Contact MedKoo:

Tel: 919-636-5577
Fax: 919-980-4831
Email: sales@medkoo.com

 

(Keyword; CAS#; MedKoo Cat#)

 

 

 

 

 

 

 

About us  |  Services  |  Products  |  News  |  Careers  |  Contact us

MedKoo Biosciences. All Rights Reserved